RAC-US Practice Questions

A.  

For at least two years after the last approval of an application in an ICH region

B.  

For a minimum of 10 years after completion of the clinical study

C.  

Three years after the last clinical study site was supplied with investigational drugs

D.  

Until the product has been discontinued from marketing in all ICH regions

A.  

Inadequate training

B.  

Late and/or incorrect deliverables

C.  

Causes of non-conformities

D.  

Adverse environmental impacts

A.  

Randomization scheme and codes

B.  

Protocol and protocol amendments

C.  

List of lECs or lRBs

D.  

Detailed CV of all investigators

A.  

Use the Madrid system.

B.  

Use the community patent system.

C.  

File patents of interest in target countries.

D.  

File design patents in target countries.

A.  

To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions

B.  

To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions

C.  

To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions

D.  

To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions